Difference between revisions of "Goserelin (Zoladex)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www1.astrazeneca-us.com/pi/zoladex3_6.pdf Goserelin (Zoladex) package insert]</ref><ref>[http://hemonc.org/doc...") |
m |
||
| (23 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http:// | + | Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis<ref name="insert">[http://documents.tersera.com/zoladex-us/10.8mg_MagnumPI.pdf Goserelin (Zoladex) package insert]</ref><ref>[[:File:Goserelin.pdf | Goserelin (Zoladex) package insert (locally hosted backup)]]</ref> |
| − | <br>Route: | + | <br>Route: SC |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | *[[Prostate cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *Patient counseling information can be found in the [http://documents.tersera.com/zoladex-us/10.8mg_MagnumPI.pdf package insert]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/goserelin.asp Goserelin (Zoladex) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/goserelin.asp Goserelin (Zoladex) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/goserelin.asp Goserelin (Zoladex) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/goserelin.asp Goserelin (Zoladex) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/goserelin-patient-drug-information Goserelin (Zoladex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/goserelin-patient-drug-information Goserelin (Zoladex) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/goserelin-patient-drug-information Goserelin (Zoladex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/goserelin-patient-drug-information Goserelin (Zoladex) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1989-12-29: Initial FDA approval for palliative treatment of advanced [[prostate cancer|carcinoma of the prostate]]. ''(Based on Pilepich et al. 1995)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | ''The approval of this drug pre-dates the EMA.'' | ||
| + | *1987-05-12: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-03-17: New additional indication for the treatment of premenopausal [[breast cancer]]. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Generic name:''' goserelin acetate | ||
| + | *'''Brand names:''' Novgos, Zoladex | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Subcutaneous medications]] | ||
| + | [[Category:GnRH agonists]] | ||
| + | |||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 1989]] | ||
| + | [[Category:EMA approved in 1987]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 18:34, 13 June 2023
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient counseling information can be found in the package insert[1]
- Goserelin (Zoladex) patient drug information (Chemocare)[3]
- Goserelin (Zoladex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1989-12-29: Initial FDA approval for palliative treatment of advanced carcinoma of the prostate. (Based on Pilepich et al. 1995)
History of changes in EMA indication
The approval of this drug pre-dates the EMA.
- 1987-05-12: EURD
History of changes in PMDA indication
- 2014-03-17: New additional indication for the treatment of premenopausal breast cancer.
Also known as
- Generic name: goserelin acetate
- Brand names: Novgos, Zoladex